nach oben

Archives of Osteoporosis

Erschienen in:

01.12.2023 | Review Article

Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Xiao Li, Jingru Han, Xiaotong Shi, Zhiguo Bi, Jianguo Liu

Erschienen in: Archives of Osteoporosis | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Objective

Periprosthetic bone mineral density (BMD) loss after total hip arthroplasty (THA) may threaten the survival of implants. Zoledronic acid (ZA) and denosumab were effective in reducing bone loss in conditions associated with accelerated bone turnover by inhibiting osteoclast activity. This meta-analysis aimed to assess the efficiency and safety of ZA and denosumab for periprosthetic BMD loss after THA.

Methods

A systematic search of randomized controlled trials (RCTs) associated with ZA or denosumab and THA was performed in MEDLINE, PubMed, Embase, the Cochrane Central Register of Controlled Trials, and the Web of Science from 1980 to 2022. Meta-analysis was performed by the Cochrane Review Manager 5 (RevMan) version 5.41. Cochrane risk of bias tool and GRADEpro were applied for methodological quality and overall evidence quality, respectively.

Results

Nine RCTs involving a total of 480 patients were finally included and analyzed. The pooled data that demonstrated significantly less periprosthetic BMD loss in Gruen zone 7 occurred in the intervention group patients than in the control group patients at 3 months (MD = 4.30, 95% CI: 1.78–6.82, P = 0.0008), 6 months (MD = 7.71, 95% CI: 5.41–10.02, P < 0.00001), and 12 months (MD = 8.19, 95% CI: 5.97–10.42, P < 0.00001) after THA. No serious adverse events (AEs) were observed.

Conclusion

In the current analysis with evidence on the efficacy and safety of ZA and denosumab, the authors recommend the use of ZA or denosumab treatment for periprosthetic bone mineral density loss.

Systematic review registration: PROSPERO registration number: CRD42022369273

Nur mit Berechtigung zugänglich

Peitgen DS, Innmann MM, Merle C, Gotterbarm T, Moradi B, Streit MR (2018) Periprosthetic bone mineral density around uncemented titanium stems in the second and third decade after total hip arthroplasty: a DXA study after 12, 17 and 21 years. Calcif Tissue Int 103(4):372–379. https://doi.org/10.1007/s00223-018-0438-9CrossRefPubMed

Nam D, Barrack RL, Clohisy JC, Nunley RM (2016) Proximal femur bone density decreases up to 5 years after total hip arthroplasty in young, active patients. J Arthroplasty 31(12):2825–2830. https://doi.org/10.1016/j.arth.2016.05.059CrossRefPubMed

Ulrich SD, Seyler TM, Bennett D, Delanois RE, Saleh KJ, Thongtrangan I, Kuskowski M, Cheng EY, Sharkey PF, Parvizi J, Stiehl JB, Mont MA (2008) Total hip arthroplasties: what are the reasons for revision? Int Orthop 32(5):597–604. https://doi.org/10.1007/s00264-007-0364-3CrossRefPubMed

Tyson Y, Rolfson O, Kärrholm J, Hailer NP, Mohaddes M (2019) Uncemented or cemented revision stems? Analysis of 2,296 first-time hip revision arthroplasties performed due to aseptic loosening, reported to the Swedish Hip Arthroplasty Register. Acta Orthop 90(5):421–426. https://doi.org/10.1080/17453674.2019.1624336CrossRefPubMedPubMedCentral

Purdue PE, Koulouvaris P, Nestor BJ, Sculco TP (2006) The central role of wear debris in periprosthetic osteolysis. HSS J 2(2):102–13. https://doi.org/10.1007/s11420-006-9003-6CrossRefPubMedPubMedCentral

Gerhardt DM, Smolders JM, Roovers EA, Rijnders TA, van Susante JL (2016) Changes in periacetabular bone mineral density five years after resurfacing hip arthroplasty versus conventional total hip arthroplasty. Hip Int 29(2):153–160. https://doi.org/10.1177/1120700018808023CrossRef

Liu Y, Xu J-W, Li M-Y, Wu L-M, Zeng Y, Shen B (2021) Zoledronic Acid for periprosthetic bone mineral density changes in patients with osteoporosis after hip arthroplasty-an updated meta-analysis of six randomized controlled trials. Front Med (Lausanne) 8:801282. https://doi.org/10.3389/fmed.2021.80128CrossRefPubMed

Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379(25):2407–2416. https://doi.org/10.1056/NEJMoa1808082CrossRefPubMed

Sköld C, Kultima K, Freyhult E, Larsson A, Gordh T, Hailer NP, Mallmin H (2022) Effects of denosumab treatment on the expression of receptor activator of nuclear kappa-B ligand (RANKL) and TNF-receptor TNFRSF9 after total hip arthroplasty-results from a randomized placebo-controlled clinical trial. Osteoporos Int 33(9):1–8. https://doi.org/10.1007/s00198-022-06423-wCrossRefPubMedPubMedCentral

10.

Delmas PD (2008) Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 11(2):325–338. https://doi.org/10.1016/j.jocd.2008.02.002CrossRefPubMed

11.

Zaheer S, LeBoff M, Michael Lewiecki E (2015) Denosumab for the treatment of osteoporosis. Expert Opin Drug Metab Toxicol 11(3):461–470. https://doi.org/10.1517/17425255.2015.1000860CrossRefPubMedPubMedCentral

12.

Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittoes NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 17(1):58. https://doi.org/10.1007/s11657-022-01061-5CrossRefPubMedPubMedCentral

13.

Dhillon S (2016) Zoledronic acid (Reclast®, Aclasta®): a review in osteoporosis. Drugs 76(17):1683–1697. https://doi.org/10.1007/s40265-016-0662-4CrossRefPubMed

14.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

15.

Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT-T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. https://doi.org/10.1136/bmj.328.7454.1490CrossRefPubMed

16.

Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R (2009) The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am 91(2):274–81. https://doi.org/10.2106/JBJS.G.01193CrossRefPubMed

17.

Scott DF, Woltz JN, Smith RR (2013) Effect of zoledronic acid on reducing femoral bone mineral density loss following total hip arthroplasty: preliminary results of a prospective randomized trial. J Arthroplasty 28(4):671–675. https://doi.org/10.1016/j.arth.2012.08.007CrossRefPubMed

18.

Lacko M, Schreierová D, Čellár R, Vaško G (2015) Bone remodeling in the proximal femur after uncemented total hip arthroplasty in patients with osteoporosis. Acta Chir Orthop Traumatol Cech 82(6):430–436CrossRefPubMed

19.

Huang TW, Wang CJ, Shih HN, Chang Y, Huang KC, Peng KT et al (2017) Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial. BMC Musculoskelet Disord 18:209. https://doi.org/10.1186/s12891-017-1577-2CrossRefPubMedPubMedCentral

20.

Aro E, Moritz N, Mattila K, Aro HT (2018) A long-lasting bisphosphonate partially protects periprosthetic bone, but does not enhance initial stability of uncemented femoral stems: a randomized placebo-controlled trial of women undergoing total hip arthroplasty. J Biomech 75:35–45. https://doi.org/10.1016/j.jbiomech.2018.04.041CrossRefPubMed

21.

Zhou W, Liu Y, Guo X, Yang H, Xu Y, Geng D (2019) Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis. Osteoporos Int 30:1581–1589. https://doi.org/10.1007/s00198-019-05005-7CrossRefPubMed

22.

Aro HT, Nazari-Farsani S, Vuopio M, Löyttyniemi E, Mattila K (2019) Effect of denosumab on femoral periprosthetic BMD and early femoral stem subsidence in postmenopausal women undergoing cementless total hip arthroplasty. JBMR Plus 3(10):e10217. https://doi.org/10.1002/jbm4.10217CrossRefPubMedPubMedCentral

23.

Zhu K, Zhang J, Zhang C, Zhao Z, Gao J, Li X et al (2021) Therapeutic efficacy of zoledronic acid combined with calcitriol in elderly patients receiving total hip arthroplasty or hemiarthroplasty for osteoporotic femoral neck fracture. Osteoporos Int 32:559–564. https://doi.org/10.1007/s00198-020-05637-0CrossRefPubMed

24.

Nyström A, Kiritopoulos D, Ullmark G, Sörensen J, Petrén-Mallmin M, Milbrink J, Hailer NP, Mallmin H (2020) Denosumab prevents early periprosthetic bone loss after uncemented total hip arthroplasty: results from a randomized placebo-controlled clinical trial. J Bone Miner Res 35(2):239–247. https://doi.org/10.1002/jbmr.3883CrossRefPubMed

25.

Finnilä S, Löyttyniemi E, Aro HT (2021) Denosumab in cementless total hip arthroplasty: multivariate reanalysis of 3D femoral stem migration and the influence on outliers. JBMR Plus 6(2):e10588. https://doi.org/10.1002/jbm4.10588CrossRefPubMedPubMedCentral

26.

Furnes O, Lie SA, Espehaug B, Vollset SE, Engesaeter LB, Havelin LI (2001) Hip disease and the prognosis of total hip replacements. A review of 53,698 primary total hip replacements reported to the Norwegian Arthroplasty Register 1987–99. J Bone Joint Surg Br 83(4):579–86. https://doi.org/10.1302/0301-620x.83b4.11223CrossRefPubMed

27.

Nagoya S, Tateda K, Okazaki S, Kosukegawa I, Shimizu J, Yamashita T (2018) Restoration of proximal periprosthetic bone loss by denosumab in cementless total hip arthroplasty. Eur J Orthop Surg Traumatol 28(8):1601–1607. https://doi.org/10.1007/s00590-018-2223-xCrossRefPubMed

28.

Ding Y, Zeng J-C, Yin F, Zhang C-L, Zhang Y, Li S-X, Liu X, Zhang C, Xue Q-Y, Lin H, Pei F-X (2017) Multicenter study on observation of acute-phase responses after infusion of zoledronic acid 5 mg in Chinese women with postmenopausal osteoporosis. Orthop Surg 9(3):284–289. https://doi.org/10.1111/os.12338CrossRefPubMedPubMedCentral

29.

Deeks ED (2018) Denosumab: a review in postmenopausal osteoporosis. Drugs Aging 35(2):163–173. https://doi.org/10.1007/s40266-018-0525-7CrossRefPubMed

30.

Hadji P, Papaioannou N, Gielen E, Feudjo Tepie M, Zhang E, Frieling I, Geusens P, Makras P, Resch H, Möller G, Kalouche-Khalil L, Fahrleitner-Pammer A (2015) Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European noninterventional study. Osteoporos Int 26(10):2479–2489. https://doi.org/10.1007/s00198-015-3164-4CrossRefPubMedPubMedCentral

31.

Fahrleitner-Pammer A, Papaioannou N, Gielen E, Feudjo Tepie M, Toffis C, Frieling I, Geusens P, Makras P, Boschitsch E, Callens J, Anastasilakis AD, Niedhart C, Resch H, Kalouche-Khalil L, Hadji P (2017) Factors associated with high 24-month persistence with denosumab: results of a real-world, noninterventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. Arch Osteoporos 12(1):58. https://doi.org/10.1007/s11657-017-0351-2CrossRefPubMedPubMedCentral

32.

Papaioannou A, Khan A, Belanger A, Bensen W, Kendler D, Theoret F, Amin Mo, Brekke L, Erdmann M, Walker V, Adachi JD (2015) Persistence with denosumab therapy among osteoporotic women in the Canadian patient-support program. Curr Med Res Opin 31(7):1391–1401. https://doi.org/10.1185/03007995.2015.1053049CrossRefPubMed

33.

Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411. https://doi.org/10.1007/s00198-015-3253-4CrossRefPubMedPubMedCentral

34.

Migliorati CA, Epstein JB, Abt E, Berenson JR (2011) Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 7(1):34–42. https://doi.org/10.1038/nrendo.2010.195CrossRefPubMed

35.

Everts-Graber J, Lehmann D, Burkard J-P, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler H-R, Reichenbach S, Lehmann T (2022) Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Miner Res 37(2):340–348. https://doi.org/10.1002/jbmr.4472CrossRefPubMed

36.

Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8(2):96–110. https://doi.org/10.14310/horm.2002.1226CrossRefPubMed

37.

Ferrari S, Lewiecki EM, Butler PW, Kendler DL, Napoli N, Huang S, Crittenden DB, Pannacciulli N, Siris E, Binkley N (2020) Favorable skeletal benefit/risk of long-term denosumab therapy: a virtual-twin analysis of fractures prevented relative to skeletal safety events observed. Bone 134:115287. https://doi.org/10.1016/j.bone.2020.115287CrossRefPubMed

38.

Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster J-Y, Singer A, Wang C, Wagman RB, Cummings SR (2016) Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101(8):3163–3170. https://doi.org/10.1210/jc.2016-1801CrossRefPubMedPubMedCentral

39.

Shanbhag AS (2006) Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg 14(4):215–225. https://doi.org/10.5435/00124635-200604000-00003CrossRefPubMed

40.

Tapaninen T, Kröger H, Venesmaa P (2015) Periprosthetic BMD after cemented and uncemented total hip arthroplasty: a 10-year follow-up study. J Orthop Sci 20(4):657–662. https://doi.org/10.1007/s00776-015-0722-8CrossRefPubMed

Titel: Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials
verfasst von: Xiao Li
Jingru Han
Xiaotong Shi
Zhiguo Bi
Jianguo Liu
Publikationsdatum: 01.12.2023
Verlag: Springer London
Erschienen in: Archives of Osteoporosis / Ausgabe 1/2023
Print ISSN: 1862-3522
Elektronische ISSN: 1862-3514
DOI: https://doi.org/10.1007/s11657-023-01227-9

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen.
» Jetzt entdecken

Neu im Fachgebiet Orthopädie und Unfallchirurgie

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Zoledronic acid and denosumab for periprosthetic bone mineral density loss after joint arthroplasty: a systematic review and meta-analysis of randomized controlled trials

Abstract

Objective

Methods

Results

Conclusion

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Diagnosis and management of osteoporosis in Saudi Arabia: 2023 key updates from the Saudi Osteoporosis Society

Association of early-life famine exposure with low bone mass in adulthood

Current approaches to secondary prevention after hip fracture in England and Wales — an analysis of trends between 2016 and 2020 using the National Hip Fracture Database (NHFD)

Adipopenia is associated with osteoporosis in community-dwelling non-underweight adults independent of sarcopenia

Efficacy and safety of odanacatib for osteoporosis treatment: a systematic review and meta-analysis

Osteoporosis-related appendicular fractures in Tikur Anbessa Specialized Hospital, Ethiopia: a prospective observational study

Arthropedia

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Ärztliche Empathie hilft gegen Rückenschmerzen

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Vorsicht mit hohen NSAR-Dosen bei ankylosierender Spondylitis!

Brustkrebs in der Vorgeschichte macht Gelenkersatz komplikationsträchtiger

Update Orthopädie und Unfallchirurgie